83 results
8-K
EX-99.1
SCYX
Scynexis Inc
28 Mar 24
SCYNEXIS Reports Full Year 2023 Financial Results
4:04pm
inventory given the potential cross-contamination of ibrexafungerp.
Research and development expense for the full year 2023 increased to $30.9 … ,
Revenue:
Product revenue, net
License agreement revenue
Total revenue
Operating expenses:
Cost of product revenue
Research and development
Selling
424B5
SCYX
Scynexis Inc
28 Nov 23
Prospectus supplement for primary offering
4:05pm
offered by us hereunder, if any, for working capital and general corporate purposes, including research and development expenses, clinical trials … corporate purposes, including research and development expenses, clinical trials and capital expenditures.
The amounts and timing of our use
424B5
SCYX
Scynexis Inc
28 Nov 23
Prospectus supplement for primary offering
4:05pm
proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development efforts and clinical trials
8-K
EX-99.1
pxpwacu6
9 Nov 22
SCYNEXIS Reports Third Quarter 2022 Financial Results
7:16am
8-K
1a0yq 4c206cl8
20 Oct 22
Termination of a Material Definitive Agreement
5:21pm